228 related articles for article (PubMed ID: 6202772)
21. dATP-mediated inhibition of DNA ligase by 2'-deoxycoformycin in T and B cell leukemia.
Lamballe F; Le Prise PY; Le Gall E; David JC
Leukemia; 1989 Feb; 3(2):97-103. PubMed ID: 2783473
[TBL] [Abstract][Full Text] [Related]
22. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.
Kurtzberg J; Hershfield MS
Cancer Res; 1985 Apr; 45(4):1579-86. PubMed ID: 3872167
[TBL] [Abstract][Full Text] [Related]
23. B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine.
Goday A; Simmonds HA; Morris GS; Fairbanks LD
Clin Exp Immunol; 1984 Apr; 56(1):39-48. PubMed ID: 6424986
[TBL] [Abstract][Full Text] [Related]
24. Characterization of three T-lymphoid cell lines with distinct sensitivities to deoxyadenosine plus deoxycoformycin.
Duan DS; Smith W; Sadée W; Cowan MJ
Thymus; 1992 Feb; 19(1):1-11. PubMed ID: 1373528
[TBL] [Abstract][Full Text] [Related]
25. Effect of 2'-deoxycoformycin infusion on S-adenosylhomocysteine hydrolase and the amount of S-adenosylhomocysteine and related compounds in tissues of mice.
Helland S; Ueland PM
Cancer Res; 1983 Sep; 43(9):4142-7. PubMed ID: 6603264
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
[No Abstract] [Full Text] [Related]
27. Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin.
Schwartz CL; Minniti CP; Harwood P; Na S; Banquerigo ML; Strauss LC; Kurtzberg J; Smith SD; Civin CI
J Clin Oncol; 1987 Dec; 5(12):1900-11. PubMed ID: 3500279
[TBL] [Abstract][Full Text] [Related]
28. Some biochemical mechanisms underlying the impairment of T and B cell immunity in C3HA mice during hepatoma growth.
Potapova GI; Khramtsova SN; Dmitrieva LV; Shapot VS
Neoplasma; 1987; 34(4):453-67. PubMed ID: 3498909
[TBL] [Abstract][Full Text] [Related]
29. Role of adenosine deaminase in lymphocyte proliferation.
Hovi T; Smyth JF; Allison AC; Williams SC
Clin Exp Immunol; 1976 Mar; 23(3):395-403. PubMed ID: 133008
[TBL] [Abstract][Full Text] [Related]
30. Increased adenosine deaminase (ADA) activity and a shift from ADA-dependent to ADA-independent phases during T-cell activation: a paradox.
Veit BC; Fishman M; Look T
J Natl Cancer Inst; 1984 May; 72(5):1151-9. PubMed ID: 6609265
[TBL] [Abstract][Full Text] [Related]
31. Action of 2'-deoxycoformycin on mitogen-induced lymphoproliferation in the neonatal period.
Romo A; Lorente F; Salazar V
Allergol Immunopathol (Madr); 1988; 16(4):243-7. PubMed ID: 3265855
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of 2'-deoxycoformycin, an inhibitor of adenosine deaminase, in the rat.
Geiger JD; Lewis JL; MacIntyre CJ; Nagy JI
Neuropharmacology; 1987 Sep; 26(9):1383-7. PubMed ID: 3499581
[TBL] [Abstract][Full Text] [Related]
33. The effects of ADA inhibition on B cell differentiation in the rat.
Barton RW
Adv Exp Med Biol; 1986; 195 Pt A():525-9. PubMed ID: 3524140
[No Abstract] [Full Text] [Related]
34. The effects of an induced adenosine deaminase deficiency on T-cell differentiation in the rat.
Barton RW
Cell Immunol; 1985 Oct; 95(2):297-310. PubMed ID: 3876160
[TBL] [Abstract][Full Text] [Related]
35. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
Svendsen KR; Overgaard-Hansen K; Frederiksen S
Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
[TBL] [Abstract][Full Text] [Related]
36. Adenosine deaminase gene amplification in deoxycoformycin-resistant mammalian cells.
Rowland P; Pfeilsticker J; Hoffee PA
Arch Biochem Biophys; 1985 Jun; 239(2):396-403. PubMed ID: 3873908
[TBL] [Abstract][Full Text] [Related]
37. Immune function in mice exposed to the adenosine deaminase inhibitor 2'-deoxycoformycin during immune system development.
Luebke RW; Lawson LD; Rogers RR; Riddle MM; Smialowicz RJ
Immunopharmacol Immunotoxicol; 1987; 9(2-3):149-61. PubMed ID: 3501794
[TBL] [Abstract][Full Text] [Related]
38. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
39. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
Bagnara AS; Hershfield MS
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
[TBL] [Abstract][Full Text] [Related]
40. Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations.
Tung R; Silber R; Quagliata F; Conklyn M; Gottesman J; Hirschhorn R
J Clin Invest; 1976 Mar; 57(3):756-61. PubMed ID: 1082452
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
